A Huntsman Cancer Institute researcher evaluated a noninvasive skin imaging technology designed to accurately distinguish between common moles and melanoma. This technology has the potential to enhance melanoma screening while potentially reducing the necessity for unnecessary biopsies.
In a press release dated February 24, 2026, researchers highlighted that the molecular imaging technology could change how melanoma is screened.
Another advancement involves the drug daraxonrasib, which researchers found could be effective against an aggressive type of skin cancer. This drug offers potential hope for patients with advanced disease who currently lack effective targeted options.
A novel oral combination drug therapy evaluated at Huntsman Cancer Institute could potentially treat and prevent melanoma from spreading to the brain. According to a press release from March 20, 2025, brain metastasis is the primary cause of death from melanoma.
Additional research highlights include studies on microbiome links to melanoma immunotherapy response and efforts to address gaps in skin cancer care for older adults and rural residents, who are more likely to receive late diagnoses of aggressive skin cancers.
